Praxis Precision Medicines公司宣布，美国食品药品监督管理局（FDA）已正式受理其针对特发性震颤患者的新药申请，该申请涉及药物盐酸Ulixacaltamide。
Praxis Precision Medicines公司宣布，美国食品药品监督管理局（FDA）已正式受理其针对特发性震颤患者的新药申请，该申请涉及药物盐酸Ulixacaltamide。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.